Navigation Links
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
Date:3/10/2008

e the potential to treat melanoma, colon cancer or other types of human cancer or that Anavex 7-1037 will provide clinically relevant advantages over other competitive compounds in development or that sigma ligands will have the potential to be a new class of drugs to treat colon cancer or other types of human cancer. Other risks that affect forward-looking information contained in this press release include the high degree of risk associated with drug development, results of further research and development, the impact of competition and of technological advances and other risks detailed to Anavex's SEC filings. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

For Further Information

-----------------------

Anavex Life Sciences Corp.

Research & Business Development

Email: info@anavex.com

Shareholder & Media Relations

Toll-free: 1-866-505-2895

Outside North America: +1 (416) 489-0092

Email: ir@anavex.com

http://www.anavex.com


'/>"/>
SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Anavex strengthens Board of Directors
2. Anavex advances drug candidate for treatment of Alzheimers disease
3. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
4. Drug Reduces Airway Mucus in Preclinical Asthma Model
5. Heavier hydrogen on the atomic scale reduces friction
6. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
7. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
8. Landfill mining reduces environmental impact of growing waste
9. Landfill mining reduces environmental impact of growing waste
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Assembly technique for tiny wires may eventually help detect cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... capital funds, investment firms and animal health companies to hear from animal health ... million. Several have also received licensing agreements or distribution contracts. This meeting ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced ... I study of BHV-0223, a glutamate modulating agent. ... BHV-0223 and recently obtained clearance from the U.S. ... human testing. Portage holds 54% equity interest in ...
(Date:8/27/2015)... GUELPH, ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. ... the three and six-month periods ended June 30, 2015. Biorem,s complete ... ( www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per ... , 2014 , 2015 , ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... 15, 2011 Generex Biotechnology Corporation ( www.generex.com ... the status of the previously announced spinout of ... ). The Company is in the ... several transaction opportunities, including both shell companies and ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... provide an overview of the company,s business strategy at ... the UBS 2011 Global Life Sciences Conference which will ... addition, Geoffrey Nichol, M.B., Ch.B., Sangamo,s executive vice president ...
... Aperion Biologics, Inc. announced that it has reached ... Company,s clinical trial of its Z-Lig™ Anterior Cruciate Ligament ... of the knee. The randomized multicenter study commenced in ... provide safety and performance data in the reconstruction of ...
Cached Biology Technology:Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference 2Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial 2
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... China , July 31, 2015 The 10 ... will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary ... one of the world,s most influential annual meetings in the ... and enjoyable scientific gatherings. ICG-10 focuses on ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... 2011 In a new study scientists at NYU Langone ... be improved. The new findings, published online November 20, 2011, ... the loss of smell due to aging or disease. ... A. Wilson, PhD, professor of child and adolescent psychiatry at ...
... University of British Columbia researchers reveals how the effect of ... fisheries practices. "Fisheries are already providing fewer fish and ... says Rashid Sumaila, principal investigator of the Fisheries Economics Research ... "We could be earning interest, but instead we,re fishing away ...
... Suitable habitat for native fishes in many Great Plains ... from the High Plains aquifer and scientists analyzing the ... Results of their study have been published in the ... be replenished seasonally with rain and snow, these regional aquifers ...
Cached Biology News:A failing sense of smell can be reversed 2Effects of climate change to further degrade fisheries resources: UBC researchers 2Great Plains river basins threatened by pumping of aquifers 2Great Plains river basins threatened by pumping of aquifers 3
... VIP (6-28) (human, bovine, porcine, ... Peptide (VIP) receptor antagonist. This ... to be twofold more potent ... receptor antagonists. ...
Protein 3D structure prediction, via threading. Easy to use....
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
Biology Products: